LIÊN KẾT WEBSITE
SHOX2 methylation in Vietnamese patients with lung cancer
Molecular Biology Reports Số 5, năm 2022 (Tập 49, trang 3413-3421)
ISSN: 3014851
ISSN: 3014851
DOI:
Tài liệu thuộc danh mục:
Article
English
Từ khóa: Antigens, Neoplasm; Asians; Biomarkers, Tumor; DNA Methylation; Homeodomain Proteins; Humans; Keratin-19; Lung Neoplasms; beta actin; cytosine; dinucleotide; epidermal growth factor receptor; homeodomain protein; short stature homeobox 2; unclassified drug; antigen CYFRA21.1; cytokeratin 19; homeodomain protein; SHOX2 protein, human; tumor antigen; tumor marker; adenocarcinoma; adult; aged; area under the curve; Article; Aspergillus; benign neoplasm; cancer growth; cancer mortality; cancer staging; controlled study; CpG island; diagnostic test accuracy study; DNA methylation; EGFR signaling; epigenetic modification; epigenetics; female; gene mutation; genetic regulation; human; human tissue; lung cancer; male; microsatellite instability; overall survival; pneumonia; real time polymerase chain reaction; receiver operating characteristic; sensitivity and specificity; tuberculosis; Vietnamese; Asian; DNA methylation; genetics; lung tumor; pathology
Tóm tắt tiếng anh
Background: DNA methylation on cytosine in the CpG dinucleotides is one of the most common epigenetic perturbations taking place during cancer initiation, progression, occurrence and resistance therapy. DNA methylation seems to be sufficiently stable epigenetic modification to be utilized as a cancer biomarker in in vitro diagnostic (IVD) settings. Nowadays, the SHOX2 methylation (mSHOX2) is one of the most valuable DNA methylation biomarkers of lung cancer that is the leading cause of cancer death. It is being continuously validated across ethnicities, lifestyles and lifespan. This study focused on characteristics of mSHOX2 in Vietnamese patients with lung cancer since a lack of investigation and evidence of its utility in this country. Methods: The probe and primer sets were designed according to the MethyLight method for quantitative assessment of the mSHOX2 in 214 formalin-fixed paraffin-embedded (FFPE) lung tissues and 57 plasma samples. Results: mSHOX2 in FFPE tissues allowed discriminating benign and malignant lung diseases with 60% (95% CI 50.7–68.8%) sensitivity and 90.4% (95% CI 82.6–95.5%) specificity. Importantly, based on mSHOX2 in plasma, lung cancer could be detected with 83.3% (95% CI 65.3–94.4%) sensitivity and 92.6% (95% CI 75.7–99.1%) specificity, respectively. There were insignificant associations between mSHOX2 with age, cancer stage, EGFR mutation and serum CEA, CYFRA21-1 concentrations except for that gender. Conclusion: Our study indicated that mSHOX2 was satisfactory for distinguishing malignant from benign lung tissue and noninvasively detecting lung cancer. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.
